Testing blood samples for cancer DNA in head and neck cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the correlation between circulating tumor DNA (ctDNA) testing and cancer relapse in patients with head and neck squamous cell carcinoma after receiving curative-intent surgery or radiation. The primary objective is to determine the rates of detectable ctDNA within two years post-treatment. Secondary objectives include assessing ctDNA prevalence at diagnosis and its association with survival outcomes and tumor volume. Participants will provide blood and tissue samples for analysis over a two-year period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants must have histologically or cytologically confirmed squamous cell carcinoma of the head and neck mucosa and skin.
2. Participants must be age \>=18 years.
3. Participants must be planning to receive curative-intent surgery or radiation-based treatment as part of standard of care treatment.
4. Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1\. Contraindication to phlebotomy for removal of 20 mL of peripheral blood each time point (up to 300 mL total over 15 time points).

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Jason W Chan, MD — University of California, San Francisco
• Study coordinator: Sonia Contreras Martinez
• Email: sonia.contrerasmartinez@ucsf.edu
• Phone: 415-514-6427

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Seeing if the first lymph node helps detect skin cancer spread earlier

  They are testing whether checking the sentinel lymph node early can help see if high-risk skin squamous cell cancer has started to spread.

  Recruiting Germans Trias i Pujol Hospital · Badalona, Barcelona · NCT07746258

• Long-term real-world follow-up of adults with cutaneous squamous cell carcinoma needing systemic treatment in France

  This study tests how adults with cutaneous squamous cell carcinoma who require systemic therapy are managed in real life, using a national French database across multiple centers.

  Recruiting at 24 sites University Hospital, Lille · Amiens and 28 other locations · NCT07606508

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Short-course (3-week) versus standard 6-week postoperative radiation for head and neck squamous cell carcinoma

  This will test whether a shorter, 3-week postoperative radiation schedule works as well as the standard 6-week schedule for adults (18–80) who had surgery for head and neck squamous cell carcinoma with certain intermediate risk features.

  Recruiting Phase 2/3 All India Institute of Medical Sciences · Jhajjar, Haryana · NCT07573956

• Iparomlimab plus tuvonralimab, with or without chemotherapy, for second-line and later recurrent or metastatic head and neck squamous cell carcinoma

  This will try whether combining two antibodies, iparomlimab and tuvonralimab, with or without chemotherapy helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after at least one systemic treatment.

  Recruiting The Second Affiliated Hospital of Hainan Medical University · Haikou, Hainan · NCT07546383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.